Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADYNOVATE prophylaxis and bleed treatment in Chinese previously treated patients with severe hemophilia A
2023-000502-26Phase 3
- Sponsor
- Baxalta
- Start
- Feb 2025
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of recombinant coagulation factor viii in hemophilia A, sponsored by Baxalta. Primary endpoint: Total Annualized Bleeding Rates.
02
Drugs
recombinant coagulation factor viii
03
Conditions
hemophilia A
Beyond the preview
Go deeper on 2023-000502-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-000502-26.